Fulminant Acute Disseminated Encephalomyelitis: A Remarkable Outcome with Cyclophosphamide

Hadas Meirson; Shelly I. Shiran; Michal Raz; Jonathan Roth; Aviva Fattal-Valevski

doi:10.1055/s-0040-1716824

Journal of Pediatric Neurology, Inhaltsverzeichnis

Journal of Pediatric Neurology 2021; 19(04): 270-275
DOI: 10.1055/s-0040-1716824

Case Report

Fulminant Acute Disseminated Encephalomyelitis: A Remarkable Outcome with Cyclophosphamide

Hadas Meirson

¹Pediatric Neurology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

,

Shelly I. Shiran

²Pediatric Radiology Unit, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

,

Michal Raz

³Department of Pathology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

,

Jonathan Roth

⁴Department of Pediatric Neurosurgery, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

,

Aviva Fattal-Valevski

¹Pediatric Neurology Institute, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

› Institutsangaben

Abstract

Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease of the central nervous system which occurs predominantly in the pediatric population. Acute treatment is high-dose intravenous glucocorticoids. Alternative treatment is usually intravenous immune globulin and/or plasma exchange. Fulminant ADEM is rare in children. Only a few cases of cyclophosphamide use in refractory ADEM have been reported. Here, we report a case of a 12-year-old girl with fulminant ADEM who was comatose and improved dramatically after cyclophosphamide administration. Cyclophosphamide treatment should be considered as a therapy in children with fulminant ADEM nonresponsive to standard therapies.

Keywords

acute disseminated encephalomyelitis - intravenous immune globulin - cyclophosphamide

Volltext

Referenzen

References
1 Erol I, Ozkale Y, Alkan O, Alehan F. Acute disseminated encephalomyelitis in children and adolescents: a single center experience. Pediatr Neurol 2013; 49 (04) 266-273
2 Leake JA, Albani S, Kao AS. et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23 (08) 756-764
3 Pavone P, Pettoello-Mantovano M, Le Pira A. et al. Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics 2010; 41 (06) 246-255
4 Noorbakhsh F, Johnson RT, Emery D, Power C. Acute disseminated encephalomyelitis: clinical and pathogenesis features. Neurol Clin 2008; 26 (03) 759-780 , ix
5 Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110 (2 Pt 1): e21
6 Tenembaum S, Chitnis T, Ness J, Hahn JS. International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007; 68 (16, Suppl 2): S23-S36
7 Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56 (10) 1308-1312
8 de Mol CL, Wong YYM, van Pelt ED. et al. Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. J Neurol 2018; 265 (06) 1310-1319
9 Yamaguchi Y, Torisu H, Kira R. et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016; 87 (19) 2006-2015
10 Xiong CH, Yan Y, Liao Z. et al. Epidemiological characteristics of acute disseminated encephalomyelitis in Nanchang, China: a retrospective study. BMC Public Health 2014; 14: 111
11 Chen Y, Ma F, Xu Y, Chu X, Zhang J. Incidence of acute disseminated encephalomyelitis in the Jiangsu province of China, 2008-2011. Mult Scler J Exp Transl Clin 2015; 1: 2055217315594831
12 Krupp LB, Banwell B, Tenembaum S. International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (16, Suppl 2): S7-S12
13 Krupp LB, Tardieu M, Amato MP. International Pediatric Multiple Sclerosis Study Group. et al; International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
14 Iype M, Kunju PAM, Saradakutty G, Anish TS, Sreedharan M, Ahamed SM. Short term outcome of ADEM: results from a retrospective cohort study from South India. Mult Scler Relat Disord 2017; 18: 128-134
15 Nishiyama M, Nagase H, Tomioka K. et al. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev 2019; 41 (06) 531-537
16 Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59 (08) 1224-1231
17 Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80 (05) 695-705
18 Miller SD, McRae BL, Vanderlugt CL. et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev 1995; 144: 225-244
19 Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol 1998; 91 (1-2): 19-27
20 Van Haren K, Tomooka BH, Kidd BA. et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler 2013; 19 (13) 1726-1733
21 Cole J, Evans E, Mwangi M, Mar S. Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria. Pediatr Neurol 2019; 100: 26-34
22 Straub J, Chofflon M, Delavelle J. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 1997; 49 (04) 1145-1147
23 Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000; 54 (06) 1370-1372
24 Khurana DS, Melvin JJ, Kothare SV. et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005; 116 (02) 431-436
25 de Seze J, Debouverie M, Zephir H. et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol 2007; 64 (10) 1426-1432
26 Yae Y, Kawano G, Yokochi T. et al. Fulminant acute disseminated encephalomyelitis in children. Brain Dev 2019; 41 (04) 373-377
27 Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009; 8 (02) 469-478
28 Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997; 42 (03) 313-318
29 Brenton JN, Banwell BL. Therapeutic approach to the management of pediatric demyelinating disease: multiple sclerosis and acute disseminated encephalomyelitis. Neurotherapeutics 2016; 13 (01) 84-95
30 Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001; 56 (10) 1313-1318
31 Rothenberg J, Lastra A, Alvarez G, Irwin R. Acute disseminated encephalomyelitis responsive to cyclophosphamide therapy: a case report. J Med Cases 2015; 6: 290-294
32 Jaskowiak JM. Treatment of hemorrhagic acute disseminated encephalomyelitis with cyclophosphamide. Am J Health Syst Pharm 2016; 73 (04) 202-205
33 Ayed H, Chaudhary MW, AlBaradie R, Mir A. Use of cyclophosphamide in a child with fulminant acute disseminated encephalomyelitis. Child Neurol Open 2018; 5: 2329048x18754631